- WRITE FOR US: The BMJ is looking for doctors and journalists to contribute articles relevant to doctors in India
- Our online table of contents is updated at least twice each day. Read all articles published in the last 7 days.
- You can use bmj.com to help you with your continuing medical education. Find out about CME/CPD credits for BMJ articles
- Keep up to date with cardiology: Access the latest cardiovascular medicine resources from across BMJ Group.
- OPEN ACCESS: All research articles are freely available online, with no word limit. Find out more about the BMJ's open access policy. Submit your paper.
- Find out how study types differ in our How to read a paper section.
Recent rapid responses
Rapid responses are electronic letters to the editor. They enable our users to debate issues raised in articles published on bmj.com. Although a selection of rapid responses will be included as edited readers' letters in the weekly print issue of the BMJ, their first appearance online means that they are published articles. If you need the url (web address) of an individual response, perhaps for citation purposes, simply click on the response headline and copy the url from the browser window.
Displaying 1-1 out of 1 published
10 October 2012
We have read this research and we think that is very important so we have made a research about the diabetic foot which is a serious health problem in Cuba and the world. Injuries resulting from this condition lead to mutilation of these patients by amputations. Cuba is keen to try to heal diabetic foot lesions. 15% of diabetics have these ulcers at some point in their lives. In Cuba in a study in hospitals in Havana in 2007 reported that 29% of patients discharged with a diagnosis of diabetic foot underwent a major amputation of one of his legs with a mortality of 10.2%.
Various treatments have been used in various diabetic foot injuries, preventive, medical and surgical, but still have not managed to reduce this cause mutilation, especially in grade IV ulcers WagnerÇ classification.
In the city of Trinidad, Cuba, a study in 31 diabetic patients undergoing treatment with Heberprot-P from January 2011 to May 2012 with the aim to analyze and elaborate the results obtained. After application of a comprehensive model of diabetic foot care, there is a significant decrease in mortality indicators after the implementation of the program of diabetes care. Cuba now has an elite product, unique in its type. This product is an epidermal growth factor (EGF). FCE is a polypeptide of 53 amino acids and 6 Kd.1954: Obtained at the Center for Genetic Engineering and Biomolecular (IGBC) in Cuba and by recombinant DNA technology, to insert the human gene in Saccharomyces cerevisiae EGF. Heberprot-P is a formulation of the human epidermal growth factor recombinant drug. Accelerates the healing of diabetic foot ulcers (UPD) deep and complex, reduces the risk of amputations in patients with UPD and contributes significantly to improving the quality of life of patients. Among the key findings is that 58.6% were between 50-59 years of age and over 50% of the patients belonged to the female gender.
Competing interests: None declared
University Policlinic. Trinidad, Cuba, 15 Colon Street
Click to like: